Key facts
- This page summarizes David S. Grayzel's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Apr 2024, 18:00.
David S. Grayzel - 09 Apr 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- Director
- Issuer ticker
- JBIO
- Reported as of
- 09 Apr 2024
- Net transaction value
- -$334,478
- SEC form
- 4
- Accepted by SEC
- 11 Apr 2024, 18:00:57 UTC
- Prior SEC filing
- 14 Aug 2024
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ommer Chohan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David S. Grayzel filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 11 Apr 2024.
Change
- Previous filing in this sequence was filed on 14 Aug 2024.
- Current net transaction value: -$334,478.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTE
transaction
Common Stock
Sale
- Transaction value
- $334,478
- Shares
- -11,882
- Change %
- -45%
- Price
- $28.15
- Shares after
- 14,502
- Date
- 09 Apr 2024
- Ownership
- By Atlas Venture Associates XII, L.P.
- Footnotes
- F1, F2, F3
AVTE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,784,730
- Date
- 09 Apr 2024
- Ownership
- By Atlas Venture Fund XII, L.P.
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The shares reported herein give effect to the pro rata distributions of shares by Atlas Venture Fund XII, L.P. ("Atlas Fund XII") for no additional consideration to its limited partners and its general partner, Atlas Venture Associates XII, L.P. ("AVA XII LP"), subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distributions of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report the distributions pursuant to Section 16.
Footnote F3
The shares are held directly by AVA XII LP. Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of the securities held by AVA XII LP, except to the extent of his pecuniary interest therein, if any.
Footnote F4
The shares are held directly by Atlas Fund XII. The general partner of Atlas Fund XII is AVA XII LP. AVA XII LLC is the general partner of AVA XII LP. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of the securities held by Atlas Fund XII, except to the extent of his pecuniary interest therein, if any.